Oncology

Sun Life's Jacques Goulet brings a background in risk management and a proven record of philanthropic impact to his new role as Chair of the MHIF.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

Aethlon Medical is advancing a device to filter pathogens from the bloodstream, viewing it as a firewall for the body's internal communication network.

In a region hit hard by lung cancer, Tanner Health proves innovation isn't just for big cities, deploying a powerful AI to save lives in Georgia and Alabama.

One year in, the Facial Pain Registry has gathered data from 740 patients, creating an unprecedented resource to fight one of medicine's most misunderstood conditions.

Polish biotech firm Urteste S.A. enrolls its first patient in a pivotal trial for a non-invasive pancreatic cancer test, a milestone in the global race for early diagnosis.

MAIA Biotechnology isn't just opening a new trial site; it's accelerating its assault on a $70B market with a drug showing remarkable early results.

Replacing a controversial task force, Canada's new NACPHS aims to modernize health guidelines with a focus on equity, patient input, and scientific agility.

HOPPR's Catalyst Program is arming global researchers with advanced tools, accelerating AI projects from cancer detection in Africa to risk prediction in the US.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.

A new partnership between software specialist Cosylab and hardware innovator Heron aims to overcome the final hurdles in deploying a promising cancer therapy worldwide.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

Facing burnout and fearing for patient safety, 250 clinicians at Seattle's top cancer centers are unionizing, challenging the very structure of modern healthcare.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

Dana-Farber's historic $50M Yawkey grant funds more than a building; it fuels a new era of integrated research and patient-centric cancer treatment.